Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

About this update from Relmada Therapeutics, Inc.

CORAL GABLES, Fla. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024 . Conference Call and Webcast Information : Date: Thursday, November 7, 2024 at 4:30 PM ET Participant Dial -in (US): 1-800-717-1738 Participant Dial -in (International): 1-646-307-1865 Conference ID Code: 60579 Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar . About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com . Investor Contact: Tim McCarthy LifeSci Advisors [email protected] Source: Relmada Therapeutics

View stock analysis, news, and events for Relmada Therapeutics, Inc.